DB
ANIK icon

Dmitry Balyasny’s Anika Therapeutics ANIK Stock Holding History

Dmitry Balyasny’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9,238
Closed -$234K – 2715
2024
Q2 		$234K Buy
+9,238
New +$239K ﹤0.01% 2295
2024
Q1 		– Sell
-14,605
Closed -$331K – 2585
2023
Q4 		$331K Buy
14,605
+4,551
+45% +$94.2K ﹤0.01% 2112
2023
Q3 		$187K Buy
+10,054
New +$209K ﹤0.01% 2043
2018
Q3 		– Sell
-12,769
Closed -$409K – 1640
2018
Q2 		$409K Buy
12,769
+7,969
+166% +$328K ﹤0.01% 1409
2018
Q1 		$239K Sell
4,800
-3,700
-44% -$209K ﹤0.01% 1696
2017
Q4 		$458K Buy
+8,500
New +$470K ﹤0.01% 1582
2017
Q1 		– Sell
-7,923
Closed -$388K – 1573
2016
Q4 		$388K Buy
7,923
+923
+13% +$42.7K ﹤0.01% 1194
2016
Q3 		$335K Buy
+7,000
New +$346K ﹤0.01% 802

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dmitry Balyasny's ANIK Position: Q3 2024 in Review

Dmitry Balyasny sold out of Anika Therapeutics (ANIK) in Q3 2024, closing a stake of 9,238 shares — an estimated $234K sold.

Dmitry Balyasny first reported a position in ANIK in Q3 2016 and held it in 8 quarters. The position peaked at $458K in Q4 2017. 122 funds tracked by Wall St. Rank hold ANIK as of Q3 2024.

  • Dmitry Balyasny reported no remaining Anika Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Dmitry Balyasny sold 9,238 Anika Therapeutics shares in Q3 2024, an estimated $234K.
  • Dmitry Balyasny first reported a position in Anika Therapeutics in Q3 2016 and held it in 8 quarters.
  • Dmitry Balyasny's Anika Therapeutics position peaked at $458K in Q4 2017.
  • 122 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.